title: Alternatives to allogeneic blood transfusions.
abstract: Inherent risks and increasing costs of allogeneic transfusions underline the socioeconomic relevance of safe and effective alternatives to banked blood. The safety limits of a restrictive transfusion policy are given by a patient's individual tolerance of acute normovolaemic anaemia. latrogenic attempts to increase tolerance of anaemia are helpful in avoiding premature blood transfusions while at the same time maintaining adequate tissue oxygenation. Autologous transfusion techniques include preoperative autologous blood donation (PAD), acute normovolaemic haemodilution (ANH), and intraoperative cell salvage (ICS). The efficacy of PAD and ANH can be augmented by supplemental iron and/or erythropoietin. PAD is only cost-effective when based on a meticulous donation/transfusion plan calculated for the individual patient, and still carries the risk of mistransfusion (clerical error). In contrast, ANH has almost no risks and is more cost-effective. A significant reduction in allogeneic blood transfusions can also be achieved by ICS. Currently, some controversy regarding contraindications of ICS needs to be resolved. Artificial oxygen carriers based on perfluorocarbon (PFC) or haemoglobin (haemoglobin-based oxygen carriers, HBOCs) are attractive alternatives to allogeneic red blood cells. Nevertheless, to date no artificial oxygen carrier is available for routine clinical use, and further studies are needed to show the safety and efficacy of these substances.
authors.affiliation: Clinic of Anoesthesiology, Intensive Care Medicine and Pain Management, J. W. Goethe University Hospital Frankfurt am Main, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany. a.pape@em.uni-frankfurt.de
authors.forename: Andreas
authors.initials: A
authors.lastname: Pape
authors.forename: Oliver
authors.initials: O
authors.lastname: Habler
mesh_terms: D000740:Anemia / Q000503:physiopathology / Q000628:therapy; D001782:Blood Donors; D001802:Blood Substitutes / Q000008:administration & dosage* / Q000145:classification / Q000191:economics; D001803:Blood Transfusion / Q000379:methods*; D003257:Consumer Product Safety / Q000592:standards; D004921:Erythropoietin / Q000008:administration & dosage; D006400:Hematocrit; D006438:Hemodilution; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007432:Intraoperative Period; D010100:Oxygen / Q000097:blood; D011300:Preoperative Care; D011994:Recombinant Proteins
chemical_list: D001802:Blood Substitutes; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D010100:Oxygen